Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
21.37 USD | -1.79% | -2.42% | -10.92% |
May. 10 | Exelixis Files Patent Complaint Against Cipla's Cancer Treatment | DJ |
May. 01 | RBC Trims Exelixis' Price Target to $27 From $28, Outperform Rating Kept | MT |
- Stock Market
- Equities
- EXEL Stock
- News Exelixis, Inc.